Guardion Health Sciences, INC. Signs Letter of Intent to Acquire Vectorvision

Our client, Guardion Health Sciences, Inc. (“Guardion”), based in San Diego, California, a leader in ocular health, technologies and products, has signed a letter of intent to acquire VectorVision, Inc., in a stock exchange transaction.

Guardion is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food product under the name Lumega-Z® that addresses a depleted macular protective pigment, which is a known risk factor for age-related macular degeneration (“AMD”), as well as computer vision syndrome (“CVS”).  Guardion has also developed a proprietary medical device, the Mapcat SF® that accurately measures the macular pigment optical density.

VectorVision is a world leader in standardizing vision testing, and the leader in the field of contrast sensitivity, glare disability and ETDRS visual acuity testing with its CSV 1000 device.  VectorVision’s testing equipment is widely used by both eye care clinicians and ophthalmic researchers and has become the established benchmark for standardized, highly sensitive and repeatable vision testing.  The acquisition of VectorVision would expand Guardion’s technical portfolio and further establish the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases.

For further information concerning Guardion, please contact Elliot H. Lutzker, Chair of our Corporate and Securities Department, at ehl@dhclegal.com or (646) 428-3210.

Related Posts